alpha-MSH analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-10. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
In the push for large research accelerators, HVEC outgrew the space available in its Cambridge auto garage. The company opened a production plant on Route 128 in Burlington, Massachusetts in 1957. At the recommendation of board member Doriot, the company also opened a Dutch subsidiary, High Voltage Engineering Europa, to supply accelerators in the European common market. Western reaction to the 1957 launch of Sputnik transformed the commercial opportunities for nuclear instrumentation. Laboratories had typically built their own accelerators from scratch. After Sputnik, the Atomic Energy Commission and National Science Foundation generously funded university and national laboratory purchases of research particle accelerators. HVEC's reliable, manufactured machines became the preferred instrument. Over fifteen years, HVEC sold 55 tandem accelerators to research laboratories in seven countries, selling each for $1–3 million. By the mid-1970s, nearly 70% of papers in experimental nuclear physics relied on data from HVEC accelerators. HVEC entered the 1960s as the nation's leading manufacturer of particle accelerators and was the single best investment ARD had made. Annual sales climbed from $1 million in 1954 to $17 million in 1962. At the time of its public listing on the New York Stock Exchange in 1963, HVEC was more than 40% of ARD's portfolio assets, having grown ARD's original $0.2M investment to $13.2 million.
The transaction moves to the due diligence phase, where the buyer makes a more detailed assessment of the property. Purchase and sale agreements will generally include clauses which require the seller to disclose certain information for buyer's review to determine if the terms of the agreement are still acceptable. The buyer may have the right to terminate the transaction and/or renegotiate the terms, often referred to as "contingencies". Many purchase agreements are contingent on the buyer's ability to obtain mortgage financing and buyer's satisfactory review of specific due diligence items. Common due diligence items include property financial statements, rent rolls, vendor contracts, zoning and legal uses, physical and environmental condition, traffic patterns and other relevant information to the buyer's purchase decision specified in the PSA. In competitive real estate markets, buyers may waive contingencies in order to make an offer more appealing to a buyer. The PSA will usually require the seller to provide due diligence information to the seller in a timely manner and limit the buyer's time to terminate the deal based on its due diligence review findings. If the buyer terminates the transaction within the due diligence timeframe, the escrow deposit is commonly returned to the buyer. If the buyer has not terminated the agreement pursuant to the PSA contingencies, the escrow deposit becomes non-refundable and failure to complete the purchase will result in the escrow deposit funds to be transferred to the seller as a fee for failure to close.
==== First operation ==== Once brought together in the seamer, the seaming head presses a first operation roller against the end curl. The end curl is pressed against the flange curling it in toward the body and under the flange. The flange is also bent downward, and the end and body are now loosely joined. The first operation roller is then retracted. At this point five thicknesses of steel exist in the seam. From the outside in they are:
=== United Kingdom === In 2008, a herd of Wagyu cattle was imported to North Yorkshire, first becoming available for consumption in 2011. Since 2011, there have been Wagyu herds in Scotland. There are British & Irish Wagyu Fullbloods registered through the British Wagyu Breeders Association.
=== Composition === Venom of the king cobra, produced by the postorbital venom glands, consists primarily of three-finger toxins (3FTx) and snake venom metalloproteinases (SVMPs). Of all the 3FTx, alpha-neurotoxins are the predominant and most lethal components when cytotoxins and beta-cardiotoxins also exhibit toxicological activities. It is reported that cytotoxicity of its venom varies significantly, depending upon the age and locality of an individual. Clinical cardiotoxicity is not widely observed, nor is nephrotoxicity present among patients bitten by this species, presumably due to the low abundance of the toxins. SVMPs are the second-most protein family isolated from the king cobra's venom, accounting from 11.9% to 24.4% of total venom proteins. The abundance is much higher than that of most cobras which is usually less than 1%. This protein family includes principal toxins responsible for vasculature damage and interference with haemostasis, contributing to bleeding and coagulopathy caused by envenomation of vipers. While there are such haemorrhagins isolated from the king cobra's venom, they only induce species-sensitive haemorrhagic and lethal activities on rabbits and hares, but with minimal effects on mice. Clinical pathophysiology of the king cobra's SVMPs has yet to be well studied, although its substantial quantity suggests involvement in tissue damage and necrosis as a result of inflammatory and proteolytic activities, which are instrumental for foraging and digestive purposes.
Sources: en.wikipedia.org
== Description == Spelt is a species of Triticum, a large stout grass similar to bread wheat. Its flowering spike is slenderer than that of bread wheat; when ripe, it bends somewhat from the vertical. The spike is roughly four-edged. The axis of the spike is brittle and divided into segments; it shatters into separate segments when fully ripe. Spelt differs from bread wheat in that each seed (a caryopsis, botanically a fruit with its wall fused to the single seed inside) stays fully encapsulated by its husk.
During an interview with the TV Insider, Holden took by surprise the news of having to sing two musical numbers after she got the role as she has never sung professionally before. To prepare herself for the musical numbers, Holden looked for a vocal coach to see if she could even sing and started to practice over three times a week to loosen her voice, in order to capture her character's Crimson Countess passion towards the chimpanzees as one of her songs would be a protest song seeking to gain awareness towards those animals. The season also includes covers of already existing songs, with two of them being Blondie's "Rapture" and Robert Mitchum's "From a Logical Point of View". Both cover songs are respectively featured in the fourth ("Glorious Five-Year Plan") and seventh episodes ("Here Comes a Candle to Light You to Bed"), and also the two are performed by Jensen Ackles. The cover for Blondie's song got a music video which depicts Ackles' character Soldier Boy making an appearance in Solid Gold, which was released on June 10, 2022, though unlike Mitchum's cover song it was not included in the season's soundtrack. Karen Fukuhara who interprets Kimiko in the series, also performs two covers of existing songs from the 1930s: "Dream a Little Dream of Me" and "I Got Rhythm". Each song was featured respectively in the first ("Payback") and fifth episodes ("The Last Time to Look on This World of Lies").
== Preceding viral infections == A number of different preceding viral infections have been reported, most commonly influenza A and B. The condition appears to be more prevalent during late fall, winter, and spring. Other virus infections that have been linked to BACM are those caused by Parainfluenza, Coxsackievirus, Adenovirus, Echovirus, and Mycoplasma pneumonia. Viral myositis after viral infections may also occur in adults, and viruses, such as COVID-19, have been reported as a rare cause of myositis.
The FBI arrests Chinese American Wanying Zhang at Los Angeles International Airport for allegedly acting as an unregistered agent of China and surveilling the family of President of Taiwan Lai Ching-te in the United States. October 5 The Trump administration authorizes a $1 billion munitions sale to the UAE for up to 10,000 Advanced Precision Kill Weapon Systems, as well as a $400 million sale of "repair and return services" for Patriot missiles to Kuwait. Trump states that he remains "always open" to direct negotiations with Tehran. The US announces that foreign financial institutions doing business with Iran may be sanctioned without warning. At a campaign rally in Nebraska, President Trump suggests that Iran could "take out" Los Angeles and San Diego while defending the economic costs of the Iran war, prompting criticism from California officials and some Republicans. The White House says his remarks were intended to highlight the threat of Iranian attacks that US military action was meant to prevent. October 6 Paramount Skydance completes its US$110 billion acquisition of Warner Bros. Discovery, in one of the largest media mergers in history. The deal combines two of Hollywood's largest film studios with major television and streaming businesses including CBS, CNN, HBO and Paramount+, with the combined company renamed Skydance Corporation. Trump authorizes execution by firing squad for Fort Hood attacker Nidal Hasan.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.